Sonic Healthcare Limited · ASX:SHL

Sonic Healthcare — Shareholder Meeting (November 2026)

38 slides from Sonic Healthcare's shareholder meeting presentation, Nov 19, 2026

  1. Slide 1: 2026 AGM - CEO Presentation and Proxy Voting Summary

    For personal use only 19 November 2026 The Manager – Listings Australian Securities Exchange Limited 39 Martin Place SYDNEY NSW 2000 Via electronic lodgement Dear Sir / Madam 2026 ANNUAL GENERAL MEETING - CEO PRESENTATION AND PROXY VOTING SUMMARY Dr Jim Newcombe, Chief Executive Officer, will presen

  2. Slide 2: Annual General Meeting

    rsonal use only Annual General Meeting 19 November 2026

  3. Slide 3: Summary of direct and proxy votes received before the AGM

    Summary of direct and proxy votes received before the AGM rsonal use only RESOLUTION FOR AGAINST OPEN ABSTAIN 1 Professor Mark Compton 267,003,647 23,754,564 1,022,139 138,121 Re-election as Director (91.51%) (8.14%) 2 Mr Neville Mitchell 277,698,266 13,035,950 1,028,140 156,115 Re-election as Direc

  4. Slide 4: CEO Presentation

    rsonal use only CEO Presentation Dr Jim Newcombe Annual General Meeting 19 November 2026

  5. Slide 5: Disclaimer

    Disclaimer Forward Looking Statements rsonal use only This presentation may include forward-looking statements about Sonic Healthcare’s financial Actual future events, results and outcomes may vary materially from the forward-looking results, guidance, business prospects and other future matters tha

  6. Slide 6: Insights from the past year

    rsonal use only Insights from the past year Sonic Healthcare Limited | 2026 Annual General Meeting 5 Bioscientia, Germany, December 2025

  7. Slide 7: Strong foundations

    rsonal use only Insights from the past year 1 Strong foundations Sonic Healthcare’s global platform and competitive differentiators provide strong foundations for long-term, sustained growth Sonic Healthcare Limited | 2026 Annual General Meeting 6

  8. Slide 8: Scale and diversification

    Insights Strong foundations for growth Scale and diversification rsonal use only Sonic Healthcare 9 11 144m 3,200 FY2026 Countries Markets Patient Patient Access is one of the Consultations Points world’s leading medical #1 in 6 markets diagnostics 343 47,658 2,400 $10.9b companies Pathologists, Lab

  9. Slide 9: Medical Leadership value cycle

    Insights Strong foundations for growth Medical Leadership value cycle Medical Leadership drives medical rsonal use only excellence and efficiency Quality Medicine Returns to shareholders and investment in high-quality medicine Medical value drives organic growth and market share gains Sonic Healthca

  10. Slide 10: Operational excellence

    Insights Strong foundations for growth Operational excellence Comprehensive hub and spoke diagnostics networks rsonal use only Industry-leading Proprietary diagnostic expert teams information systems s l Best-in-class Strategic global equipment, systems procurement program and facilities Sophisticat

  11. Slide 11: Sonic Healthcare's investment proposition

    Insights Strong foundations for growth rsonal use only Sonic Healthcare’s investment proposition We deliver high-value medicine at scale, driving growth and financial performance Sonic Healthcare Limited | 2026 Annual General Meeting 10

  12. Slide 12: Significant opportunities ahead

    rsonal use only Insights from the past year Significant 2 opportunities ahead Industry trends and untapped potential within Sonic Healthcare create opportunities for growth and improved returns Sonic Healthcare Limited | 2026 Annual General Meeting 11

  13. Slide 13: Leveraging our strengths to accelerate growth

    Insights Significant opportunities ahead Leveraging our strengths to accelerate growth Industry Trends Sonic Healthcare’s Competitive Advantages rsonal use only Growing demand for healthcare services Leading market positions and high-volume, Ageing populations, new tests and increasing consumer need

  14. Slide 14: Federation 2.0 – optimising our federated structure

    Insights Significant opportunities ahead Federation 2.0 – optimising our federated structure will create greater financial value rsonal use only Federated Strengths Global Opportunities Financial Value • Trusted local branding • Addressing new markets Strong, sustained revenue growth • Strong custom

  15. Slide 15: Clear alignment on financial outcomes

    rsonal use only Insights from the past year Clear alignment on 3 financial outcomes Focus on EPS and ROIC growth in decision-making will drive shareholder value Sonic Healthcare Limited | 2026 Annual General Meeting 14

  16. Slide 16: Disciplined execution to drive shareholder value

    Insights Internal alignment Disciplined execution to drive shareholder value rsonal use only Comprehensive internal alignment on key financial outcomes Expanded Rigorous investment Robust business Refined global project performance-based assessment case analysis management framework remuneration str

  17. Slide 17: FY2026 review

    rsonal use only FY2026 review Sonic Healthcare Limited | 2026 Annual General Meeting 16

  18. Slide 18: Solid financial results with EBITDA guidance achieved

    FY2026 Review Solid financial results with EBITDA guidance achieved rsonal use only REVENUE ORGANIC REVENUE GROWTH EBITDA $10,867m 5% $1,933m 13% year-on-year Track record of strong growth 11% year-on-year NET PROFIT EARNINGS PER SHARE ROIC $621m 125.6c 6.5% 17% year-on-year 14% year-on-year +60bps

  19. Slide 19: Strong execution across key initiatives

    FY2026 Review Strong execution across key initiatives rsonal use only Acquisition synergy Key growth initiatives US operating review realisation on track outperforming delivering benefits LADR (Germany): >40% of total Advanced diagnostics: double- Cost reduction initiatives, expected synergies achie

  20. Slide 20: Investment-grade balance sheet

    FY2026 Review Investment-grade balance sheet rsonal use only Credit Metrics 30 June 2026 30 June 2025 Net interest-bearing debt A$m 3,069 2,818 Equity A$m 8,493 8,473 Debt cover X 2.2 2.1 Gearing ratio % 25.9 24.7 Interest cover X 10.0 10.1  Increase in net debt largely relates to acquisitions of L

  21. Slide 21: Progressive dividend maintained

    FY2026 Review Progressive dividend maintained rsonal use only A$ FY2026 FY2025 Growth Interim Dividend $0.45 $0.44 2.3% Final Dividend $0.63 $0.63 0% Total Dividends $1.08 $1.07 0.9%  Dividend franked to 60%  Expect future earnings growth to support achievement of the target dividend payout ratio

  22. Slide 22: Capital management – property transactions

    FY2026 Review Capital management – property transactions rsonal use only Artist’s rendering Sale and Leaseback Completed Conditional Contract Signed Bowen Hills, Brisbane 95 Epping Rd, Macquarie Park, Sydney  Completed sale and leaseback to Charter Hall for a  Sale of surplus property purchase pri

  23. Slide 23: Global digital and AI transformation

    FY2026 Review Global digital and AI transformation Commenced strategic initiatives in FY2026 to modernise Sonic Healthcare’s global digital rsonal use only infrastructure, improving productivity and creating a foundation for responsible use of AI Modernising finance, supply chain and HR systems to l

  24. Slide 24: Strengthening leadership structures and roles

    FY2026 Review Strengthening leadership structures and roles rsonal use only New Leadership Structures Sonic Healthcare Germany Sonic Healthcare Australia 11 federation members combined into three Increased collaboration across pathology, operating divisions to accelerate synergy capture radiology, c

  25. Slide 25: Sustainability

    rsonal use only Sustainability Sonic Healthcare Limited | 2026 Annual General Meeting 24

  26. Slide 26: Sustainability Impact Report and ESG ratings

    FY2026 Review Sustainability Impact Report and ESG ratings rsonal use only sonichealthcare.com/sustainability Sonic Healthcare Limited | 2026 Annual General Meeting 25

  27. Slide 27: Sustainability highlights

    FY2026 Review Sustainability highlights ENVIRONMENT OUR PEOPLE COMMUNITIES GOVERNANCE rsonal use only 10% 41% 99% 144 million ✓ Reduction in scope 2 Hybrid or electric motor Staff access to an Patient consultations Continued improvement of market-based emissions vehicles in global fleet employee ass

  28. Slide 28: Sonic Healthcare Foundation

    FY2026 Review Sonic Healthcare Foundation Improving the health and wellbeing of communities around the world through healthcare infrastructure, rsonal use only diagnostics, training and preventative care 30 years in Africa The opening of Sonic Kworo Hospital in north Uganda represents the most signi

  29. Slide 29: Global Leaders Summit 2026

    rsonal use only Global Leaders Summit 2026

  30. Slide 30: Leaders from across Sonic Healthcare

    Global Leaders Summit Leaders from across Sonic Healthcare rsonal use only Sonic Healthcare | 2026 Annual General Meeting 29

  31. Slide 31: Strategies to grow shareholder value

    Global Leaders Summit Strategies to grow shareholder value rsonal use only Grow and Deliver high-quality diversify revenue care at higher margins Broaden the customer base with Scale automation, robotics and AI to enhanced digital access and new grow capacity and reduce cost channels Expand personal

  32. Slide 32: Expand personalised and precision medicine

    Global Leaders Summit Expand personalised and precision medicine Leveraging Sonic Healthcare’s strengths in advanced diagnostics rsonal use only Women’s Health Neurology Mental Health Longevity  Prenatal care and maternal-  Alzheimer’s disease  Pharmacogenomics  Biological age testing fetal medi

  33. Slide 33: FY2027 outlook

    rsonal use only FY2027 outlook Sonic Healthcare Limited | 2026 Annual General Meeting 32

  34. Slide 34: FY2027 guidance update

    FY2027 Outlook FY2027 guidance update rsonal use only Key guidance EBITDA guidance reaffirmed after four months’ trading considerations  EBITDA A$1,950 – A$2,030 million (constant currency), excluding  Excludes any gains from sale of back-office IT systems transformation costs of ~A$30 million pro

  35. Slide 35: FY2027 updates

    FY2027 Outlook FY2027 updates rsonal use only Organic revenue growth for key markets  Organic revenue growth YTD October (constant currency) in line with YTD October 20261 expectation at 4.4%1  Strong organic growth rates in major markets Germany 4%  Continued momentum in key growth areas, includ

  36. Slide 36: Key takeaways

    Key takeaways rsonal use only Sonic Healthcare has strong foundations and significant untapped potential. Our focus is on converting that potential into stronger earnings, improved returns and long-term shareholder value. Deliver on the Optimise our Pursue growth operational and federated structure

  37. Slide 37: Sonic Healthcare's global people

    Sonic Healthcare’s global people Caring for our communities rsonal use only Sonic Healthcare Limited | 2026 Annual General Meeting 36

  38. Slide 38: Thank you

    y Thank you SONIC HEALTHCARE c) ersonal use onl = C4

Sonic Healthcare — Shareholder Meeting (November 2026) on 6ix